VERAXA Biotech (NASDAQ: VRXA) announced on July 20 that it has received Scientific Advice from Germany's Paul-Ehrlich-Institute (PEI), providing regulatory feedback on the biological rationale and proposed non-clinical development strategy for its lead BiTAC®-TCE program. This milestone marks progress for the company as it advances its proprietary bispecific T-cell engager platform toward clinical development. The regulatory guidance, detailed in a press release issued on July 23, 2026, helps reduce development uncertainty by providing greater clarity before the company initiates clinical studies (https://ibn.fm/zBiDU).
Scientific Advice procedures allow drug developers to consult with regulatory experts before clinical trials begin, aligning development strategies with regulatory expectations regarding safety, tolerability, and non-clinical plans. For VERAXA, the PEI's feedback supports the company's proposed biological rationale and safety assessments, offering early guidance on its novel therapeutic platform. The company's lead BiTAC®-TCE candidate previously generated encouraging preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting, reinforcing the potential of this approach.
VERAXA continues to build a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (ADCs), and other engineered antibody formats. The latest regulatory milestone follows continued progress in manufacturing and development as the company advances next-generation antibody therapeutics for cancer. Investors can find more information and updates on VERAXA in the company's newsroom at https://ibn.fm/VRXA.
Forward-looking statements in this article involve risks and uncertainties, including those set forth under "Risk Factors" in the company's SEC filings. The company undertakes no duty to update this information unless required by law.
